Redx Pharma (LSE:REDX) Interest Income : £1.22 Mil (TTM As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Redx Pharma Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Redx Pharma's interest income for the six months ended in Sep. 2023 was £0.52 Mil. Its interest income for the trailing twelve months (TTM) ended in Sep. 2023 was £1.22 Mil.

Redx Pharma Interest Income Historical Data

The historical data trend for Redx Pharma's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redx Pharma Interest Income Chart

Redx Pharma Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Interest Income

Get a 7-Day Free Trial

0.01

0.19

1.22

Redx Pharma Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Interest Income	Get a 7-Day Free Trial															0.01	0.01	0.18	0.70	0.52

Redx Pharma Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £1.22 Mil.

Redx Pharma (LSE:REDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Redx Pharma PLC (LSE:REDX) » Definitions » Interest Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

Block 33, Mereside, Alderley Park, Macclesfield, GBR, SK10 4TG

Website

https://www.redxpharma.com

Redx Pharma PLC is a United Kingdom-based biotechnology company focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases. Its product pipeline under development includes Porcupine Inhibitor, ROCK2 Selective Inhibitor, GI-targeted ROCK inhibitor, Pan-RAF Inhibitor, and others. The firm operates geographically in UK and Ireland. Revenue is generated from; Scientific programmes and research collaboration, Research collaboration and Research and preclinical development services. Redx is a clinical-stage biotechnology company focused on the discovery & development of novel, small-molecule, targeted medicines for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis.

Redx Pharma (LSE:REDX) Headlines

No Headlines